Skip to content
Research Article Open access CC BY 4.0

COVID-19 in Libya: Immunity and Protective Measures?

Moftah Hussin Alhagamhmad, Ahmad Abdulkader, Saleh Megil

Asian Journal of Research in Infectious Diseases · pp. 1–4 · Published 21 Jul 2020

10.9734/ajrid/2020/v4i330146

Abstract

Coronavirus Disease 2019 (COVID-19) is a pandemic illness and so far, there are almost 8860331 confirmed infected cases worldwide concentrating mainly in Americas and Europe, whereas data are less prominent in African countries. In Libya, the preliminary reports revealed there are small numbers of COVID-19 confirmed cases, which subsequently showed only a steady rise with no yet a clear explanation. In way we might find a reason behind Libya having a relatively small number of COVID-19 cases, the literature therefore was searched for all relevant journal articles and published reports that dealt with COVID-19 outbreaks. According to the latest released data, the incidence rate of COVID-19 in Libya remained relatively low as compared to the other countries, where only 571 out of almost nine millions total confirmed cases across the globe were documented in Libya. Further, there is a strong claim that Bacillus Calmette-Guérin (BCG) vaccine, a part of national immunization program of many countries including Libya, might offer at least a partial protection against COVID-19. Cross-protective immunity triggered by other related viral infections is an additional immunological theory might explain the current low trend of COVID-19 epidemic in Libya.

COVID-19 epidemiology BCG immunity

References (13)

  1. 1 World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19) [DOI]
  2. 2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges [DOI]
  3. 3 Systematic review of COVID‐19 in children shows milder cases and a better prognosis than adults [DOI]
  4. 4 BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity [DOI]
  5. 5 Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity [DOI]
  6. 6 Non-specific effects of BCG vaccine on viral infections [DOI]
  7. 7 Preliminary epidemiological analysis of suspected cases of corona virus infection in Libya [DOI]
  8. 8 A COVID-19 case in Libya acquired in Saudi Arabia [DOI]
  9. 9 Evidence for Cross-Protection Against Subsequent Febrile Respiratory Illness Episodes From Prior Infections by Different Viruses Among Singapore Military Recruits 2009–2014 [DOI]
  10. 10 COVID-19 in Libya: Fewer Cases So Far. Any Speculations? [DOI]
  11. 11 STATISTICAL report of WHO/UNICEF BCG vaccination programmes.
  12. 12 Correlation between universal BCG vaccination policy and reduced mortality for COVID-19 [DOI]
  13. 13 COVID-19 vaccination clinical trials should consider multiple doses of BCG [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

59

Page views

0

PDF downloads

17

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.